Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Editas Medicine, Inc. (EDIT) is a Biotechnology company based in US with a market capitalization of $282.9M. Revenue grew 25.4% year-over-year and free cash flow was negative at -$165.8M. This page tracks EDIT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 246 employees · IPO Feb 3, 2016
Valuation
Valuation & price
$2.62as of May 17, 2026· -36.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
10.37
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$282.9M
Market cap
25.4%
Revenue growth (YoY)
100.0%
Gross margin
-$165.8M
Free cash flow (USD)
-$69.9M
Net debt
Net cash position
7.8%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 5, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 18, 2026Filing
Annual Meeting Results
- Insider sellJun 5, 2026Filing
Insider Sell $2KBurkly Linda · EVP, CHIEF SCIENTIFIC OFFICER · $2K
- Insider sellJun 5, 2026Filing
Insider Sell $42KO'Neill Gilmore Neil · Director, CEO · $41.5K
- Insider sellJun 5, 2026Filing
Insider Sell $1KParison Amy · SVP, Chief Financial Officer · $1.3K
- 8-K eventMay 26, 2026Filing
Preclinical Data Presentation
- 8-K eventMay 26, 2026Filing
Sales Agreement Termination
- 8-K eventMay 26, 2026Filing
Warrant Issuance
- 8-K eventMay 14, 2026Filing
Preclinical Data Report
- 8-K eventMay 5, 2026Filing
Earnings Release
- Quarterly reportMay 5, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Editas Medicine, Inc.'s market cap?
Editas Medicine, Inc. (EDIT) has a market capitalization of $282.9M.
What is EDIT's P/E ratio?
A meaningful P/E ratio is not available for EDIT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is EDIT's price-to-book (P/B) ratio?
EDIT trades at 10.37 times book value per share.
Are insiders buying EDIT stock?
SEC Form 4 filings show no open-market insider buys at Editas Medicine, Inc. in the last 90 days (3 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.